Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the GLP-1 and GIP receptors. VKTX is ...
A small study suggests every-other-week GLP-1 shots could be enough for locking in weight loss — but there are caveats. In a small new study, most people who switched from weekly to every-other-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback